BioGeneration Ventures

BioGeneration Ventures
Last activity: 12.03.2024
Invests in categories: DrugTechnologyDevelopmentPlatformBioTechMedtechHealthTechResearchProductDiagnostics
BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech, medtech, and diagnostics companies. BGV has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €100 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together. BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realisation for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit. Historical successful investments include divestment of Dezima Pharma to Amgen for up to USD 1.55 billion in total deal value and in Acerta Pharma for up to USD 7 billion with a guaranteed payment of USD 4 billion. Both companies were co-founded by BGV in 2012 and 2013 respectively. The Acerta Pharma sale was the largest exit ever of a privately held European biotech company. BGV is based in Naarden, The Netherlands, and closely collaborates with Forbion.
Location: Netherlands, North Holland, Naarden
Employees: 11-50
Founded date: 2006
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A

Portfolio 24

DateNameWebsiteTotal RaisedLocation
25.02.2022Complement...complement...$84.66MUnited Kin...
18.08.2021Mironid®$6.31MUnited Kin...$37.72M-
03.08.2021Dezima Pha...investors....-United Sta...
03.08.2021Progentix ...progentix....--
Show more

Mentions in press and media 23

12.03.2024Azafaros announces completion of 12-week Phase 2 RAINBOW stu...Major milestone reached in bringing new treatment options to patients and their families Leiden,
02.10.2023'The fundamentals are really strong': Why investors are stay...While the biotech bull market hasn’t charged back in 2023 as many had hoped, European-focused ventur...fiercebiot...
19.07.2023Dutch biotech River BioMedics raises €2M to discover, develo...Read this article in: Enschede-based River BioMedics, a Dutch biotech company focused on cardiac dru...siliconcan...
13.07.2023BioGeneration Ventures Closes BGV Fund V, at €150MBioGeneration Ventures (BGV), a Naarden, The Netherlands-based early-stage VC in European biopharma,
11.05.2023Il mercato del Venture Capital ad aprile 2023Come è andato il mercato del Venture Capital ad aprile 2023? Facciamo insieme una carrellata delle s...startup-ne...
18.11.2022FundaMental Pharma launches with EUR 10 million in Seed fina...November 17,
26.09.2022Amsterdam-based Phosphoenix bags funds to help blind people ...Amsterdam-based Phosphoenix, a company that is working to help blind people regain functional vision...siliconcan...
01.10.2021BGV closes $110M fundBenhamou Global Ventures has raised $110 million for its fourth flagship fund. The Palo Alto-based V...pitchbook....
30.09.2021BGV closes fourth fund with $110M aimed at immigrant enterpr...Silicon Valley-based venture capital (VC) firm Benhamou Global Ventures, known as BGV, closed its fo...techcrunch...
09.07.2020VarmX raises €32M in Series B financing to develop innovativ...08/07/2020 Press release VARMX RAISES €32 MILLION IN SERIES B FINANCING TO DEVELOP INNOVATIVE REVE...webcapital...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In